As an affiliate of Servier – and being the Center of excellence for Antibodies – our strategic focus is to apply our streamlined and effective antibody platform and capabilities –  in the discovery and early development of highly differentiated antibody therapeutics. Symphogen has over the years proven our ability to deliver unique antibodies mainly within oncology and we have taken a number of projects from target to lead and further into clinical phases. After the integration with Servier we have expanded our activities also to cover immune inflammatory molecules – and at the moment our pipeline reflects this. Thus, our current  pipeline covers both oncology and immunoinflammatory projects. Please follow this link to Servier’s development pipeline.